Generation of a human IgM monoclonal antibody directed against HLA class II molecules: A potential agent in the treatment of haematological malignancies

Cancer Immunology, Immunotherapy

Volumn 58, Issue 3, 2009, Pages 351-360

  Díaz, Belén ^a   Sanjuan, Irene ^b   Gambón, Francisco ^b   Loureiro, Carmen ^b   Magadán, Susana ^c   González–Fernández, África ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c Inst Sup de Saude do Alto Ave   (Portugal)

Author keywords

HLA class II; Human monoclonal antibodies; Immunotherapy; Leukaemia

Indexed keywords

CYTOKINE; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BH 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CELL KILLING; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; MALE; MOUSE; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SERUM; TRANSGENIC MOUSE; TUMOR CELL;

EID: 58149289468     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-008-0558-6     Document Type: Article

References (38)

1. GP Adams LM Weiner 2005 Monoclonal antibody therapy of cancer Nat Biotechnol 23 1147 1157
2. M Brüggemann HM Caskey C Teale H Waldmann GT Williams MA Surani MS Neuberger 1989 A repertoire of monoclonal antibodies with human heavy chains from transgenic mice Proc Natl Acad Sci 86 17 6709 6713
3. M Brüggemann C Teale M Clark C Bindon H Waldmann 1989 A matched set of rat/mouse chimeric antibodies identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha J Immunol 142 3145 3150
4. T Burgess A Coxon S Meyer J Sun K Rex T Tsuruda Q Chen SY Ho L Li S Kaufman K McDorman RC Cattley J Sun G Elliott K Zhang X Feng XC Jia L Green R Radinsky R Kendall 2006 Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met- dependent human tumors Cancer Res 66 1721 1729
5. C Carlo-Stella M Di Nicola MC Turco L Cleris C Lavazza P Longoni M Milanesi M Magni M Ammirante A Leone Z Nagy WR Gioffre F Formelli AM Gianni 2006 The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice Cancer Res 66 1799 1808
6. C Carlo-Stella A Guidetti M Di Nicola P Longoni L Cleris C Lavazza M Milanesi R Milani M Carrabba L Farina F Formelli AM Gianni P Corradini 2006 CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice Exp Hematol 34 721 727
7. C Carlo-Stella A Guidetti M Di Nicola C Lavazza L Cleris D Sia P Longoni M Milanesi M Magni Z Nagy P Corradini A Carbone F Formelli AM Gianni 2007 IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 Cancer Res.1 67 7 3269 3275
8. CG Davis XC Jia X Feng M Haak-Frendscho 2004 Production of human antibodies from transgenic mice Methods Mol Biol 248 191 200
9. M Dechant J Bruenke T Valerius 2003 HLA class II antibodies in the treatment of hematologic malignancies Semin Oncol 30 465 475
10. M Dechant G Vidarsson B Stockmeyer R Repp MJ Glennie M Gramatzki JG van de Winkel T Valerius 2002 Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing Blood 100 4574 4580
11. GL Denardo E Tobin K Chan BM Bradt SJ Denardo 2005 Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies Clin Cancer Res 11 7075s 7079s
12. MA Epstein BG Achong YM Barr B Zajac G Henle W Henle 1966 Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji) J Natl Cancer Inst 37 4 547 559
13. LK Gilliland LA Walsh MR Frewin MP Wise M Tone G Hale D Kioussis H Waldmann 1999 Elimination of the immunogenicity of therapeutic antibodies J Immunol 162 3663 3671
14. J Golay L Zaffaroni T Vaccari M Lazzari GM Borleri S Bernasconi F Tedesco A Rambaldi M Introna 2000 Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 95 3900 3908
15. KM Haan WW Kwok R Longnecker P Speck 2000 Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor J Virol 74 5 2451 2454
16. G Hale S Cobbold N Novitzky D Bunjes R Willemze HG Prentice D Milligan S MacKinnon H Waldmann 2001 CAMPATH-1 antibodies in stem-cell transplantation Cytotherapy 3 145 164
17. P Hu MS Glasky A Yun MM Alauddin JL Hornick LA Khawli AL Epstein 1995 A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system Hum Antibodies Hybridomas 6 2 57 67
18. JD Isaacs MG Wing JD Greenwood BL Hazleman G Hale H Waldmann 1996 A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans Clin Exp Immunol 106 427 433
19. G Köhler C Milstein 1975 Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 495 497
20. C Liu G DeNardo E Tobin S DeNardo 2004 Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells Cancer Biother Radiopharm 19 545 561
21. N Lonberg 2005 Human antibodies from transgenic animals Nat Biotechnol 23 1117 1125
22. S Magadán M Valladares E Suárez I Sanjuán A Molina C Ayling SL Davies X Zou GT Williams MS Neuberger M Brüggemann F Gambón F Díaz-Espada A González-Fernández 2002 Production of antigen-specific human monoclonal antibodies: comparison of mice carrying IgH/kappa or IgH/kappa/lambda transloci Biotechniques 33 680 See also 682,684
23. B Mavromatis BD Cheson 2003 Monoclonal antibody therapy of chronic lymphocytic leukemia J Clin Oncol 21 1874 1881
24. A Molina M Valladares S Magadán D Sancho F Viedma I Sanjuán F Gambón F Sánchez-Madrid A González-Fernández 2003 The use of transgenic mice for the production of a human monoclonal antibody specific for human CD69 antigen J Immunol Methods 282 147 158
25. AP Mone P Huang H Pelicano CM Cheney JM Green JY Tso AJ Johnson S Jefferson TS Lin JC Byrd 2004 Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells Blood 103 1846 1854
26. ZA Nagy B Hubner C Lohning R Rauchenberger S Reiffert E Thomassen-Wolf S Zahn S Leyer EM Schier A Zahradnik C Brunner K Lobenwein B Rattel M Stanglmaier M Hallek M Wing S Anderson M Dunn T Kretzschmar M Tesar 2002 Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells Nat Med 8 801 807
27. Flomenberg N, Knowles RW, Williams D, Horibe K, Rosenkrantz K, Dupont B (1985) T lymphocyte clones detecting novel supertypic HLA class II allospecificities, vol 22. Springer, Berlin, pp 270-300
28. IC Nicholson X Zou AV Popov GP Cook EM Corps S Humphries C Ayling B Goyenechea J Xian MJ Taussig MS Neuberger M Brüggemann 1999 Antibody repertoires of four- and five-feature translocus mice carrying human immunoglobulin heavy chain and kappa and lambda light chain yeast artificial chromosomes J Immunol 163 6898 6906
29. T Ostendorf CR van Roeyen JD Peterson U Kunter F Eitner AJ Hamad G Chan XC Jia J Macaluso G Gazit-Bornstein BA Keyt HS Lichenstein WJ LaRochelle J Floege 2003 A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis J Am Soc Nephrol 14 2237 2247
30. VA Oxelius M Aurivillius AM Carlsson K Musil 1999 Serum Gm allotype development during childhood Scand J Immunol 50 440 446
31. M Rouleau R Namikawa S Antonenko N Carballido-Perrig MG Roncarolo 1996 Antigen-specific cytotoxic T cells mediate human fetal pancreas allograft rejection in SCID-hu mice J Immunol 157 12 5710 5720
32. V Quaranta F Indiveri MC Glassy A Ng C Russo GA Molinaro MA Pellegrino S Ferrone 1980 Serological, functional, and immunochemical characterization of a monoclonal antibody (MoAb Q2/70) to human Ia-like antigens Hum Immunol 1 211 223
33. JD Shi C Bullock WC Hall V Wescott H Wang DJ Levitt CK Klingbeil 2002 In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells Leuk Lymphoma 43 1303 1312
34. E Suárez S Magadán I Sanjuán M Valladares A Molina F Gambón F Díaz-Espada A González-Fernández 2006 Rearrangement of only one human IGHV gene is sufficient to generate a wide repertoire of antigen specific antibody responses in transgenic mice Mol Immunol 43 1827 1835
35. T Tawara K Hasegawa Y Sugiura T Tahara I Ishida S Kataoka 2007 Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas Cancer Sci 98 921 928
36. SP Treon C Mitsiades N Mitsiades G Young D Doss R Schlossman KC Anderson 2001 Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies J Immunother 24 263 271
37. XD Yang XC Jia JR Corvalan P Wang CG Davis 2001 Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy Crit Rev Oncol Hematol 38 17 23
38. F Ziller P Macor R Bulla D Sblattero R Marzari F Tedesco 2005 Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 Eur J Immunol 35 2175 2183